



a.) Amendment to the Claims

Claims 1-19 (Cancelled).

20. (Original) A method of treating an anxiety disorder, comprising administering an effective amount of a xanthine derivative represented by formula (I):




[wherein  $R^1$ ,  $R^2$  and  $R^3$  independently represent hydrogen, lower alkyl, lower alkenyl or lower alkynyl;  $R^4$  represents cycloalkyl,  $-(CH_2)_n-R^5$  (in which  $R^5$  represents substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group; and  $n$  is an integer of 0 to 4) or formula (I-i)




(in which  $Y^1$  and  $Y^2$  independently represent hydrogen, halogen or lower alkyl; and  $Z$  represents substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group); and  $X^1$  and  $X^2$  independently represent O or S], or a pharmaceutically acceptable salt thereof.


21. (Original) The method of treating an anxiety disorder according to claim 20 wherein the xanthine derivative is a compound represented by formula (I-A):



[wherein  $R^{1a}$  and  $R^{2a}$  independently represent methyl or ethyl;  $R^{3a}$  represents hydrogen or lower alkyl; and  $Z^a$  represents formula (I-ii)]




(in which  $R^6$  represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro or amino; and m represents an integer of 1 to 3) or formula (I-iii)]




(in which at least one of  $R^7$ ,  $R^8$  and  $R^9$  represents lower alkyl or lower alkoxy and the others represent hydrogen;  $R^{10}$  represents hydrogen or lower alkyl)], or a pharmaceutically acceptable salt thereof.

22. (Previously Presented) The method of treating an anxiety disorder according to claim 20 wherein the xanthine derivative is a compound represented by formula (I-B):



wherein R<sup>1b</sup> and R<sup>2b</sup> independently represent hydrogen, propyl, butyl, lower alkenyl or lower alkynyl; R<sup>3b</sup> represents hydrogen or lower alkyl; Z<sup>b</sup> represents substituted or unsubstituted naphthyl, or formula (I-ii)



or a pharmaceutically acceptable salt thereof.

23. (Previously Presented) The method of treating an anxiety disorder according to claim 20 wherein the xanthine derivative is (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof.

24. (Original) The method of treating an anxiety disorder according to any one of claims 20 to 23, wherein the anxiety disorder is generalized anxiety disorder.

25. (Currently Amended) A method of treating an anxiety disorder, comprising administering, to a patient in need thereof, an effective amount of at least one ~~adenosine A<sub>2A</sub> receptor antagonist~~ xanthine derivative or pharmaceutically acceptable salt thereof according to any one of claims 20 to 23 in combination with an anxiolytic ~~other than~~ which does not have adenosine A<sub>2A</sub> receptor antagonist activity ~~the adenosine A<sub>2A</sub> receptor antagonist to a patient in need thereof~~.

Claims 26-30 (Cancelled).

31. (Currently Amended) The method of treating an anxiety disorder according to any one of ~~claims 25 to 30~~ claims 20 to 23, wherein the anxiety disorder is panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, ~~generalized anxiety disorder~~ or specific phobia.

Claims 32-68 (Cancelled).

69. (New) The method of treating an anxiety disorder according to claim 25, wherein the anxiety disorder is generalized anxiety disorder.

70. (New) The method of treating an anxiety disorder according to claim 25, wherein the anxiety disorder is panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder or specific phobia